Long-term tolerance and efficacy of siltuximab (anti-IL-6) in a young adult with idiopathic multicentric Castleman disease during COVID-19
  • Helbies Bedier
    Division of Hematology, McGill University Health Centre, Montreal, Canada; Infectious Diseases and Immunity in Global Health, Research Institute of the McGill University Health Centre, Montreal, Canada
  • Stéphane Isnard
    Infectious Diseases and Immunity in Global Health, Research Institute of the McGill University Health Centre, Montreal, Canada; Chronic Viral Illness Service, McGill University Health Centre, Montreal, Canada
  • Chelsea Maedler-Kron
    Department of Laboratory Medicine/Pathology, Division of Pathology, McGill University Health Centre, Montreal, Canada
  • Jean-Pierre Routy
    Division of Hematology, McGill University Health Centre, Montreal, Canada; Infectious Diseases and Immunity in Global Health, Research Institute of the McGill University Health Centre, Montreal, Canada; Chronic Viral Illness Service, McGill University Health Centre, Montreal, Canada

Keywords

lymphoproliferative disorders, multicentric Castleman disease, siltuximab, IL-6, COVID-19

Abstract

Background: Castleman disease (CD) is a rare lymphoproliferative disorder with various subtypes, including the HHV-8-negative/idiopathic multicentric CD (iMCD). The diagnosis of iMCD remains challenging due to its non-specific presentation, in the form of generalised lymphadenopathies and inflammation. Two clinical presentations have been recently defined: a severe form iMCD-TAFRO and a milder form of iMCD not otherwise specified (iMCD-NOS). identification of interleukin-6 (IL-6) as a major culprit of inflammatory symptoms led to the development of anti-IL-6 therapies, with siltuximab being the approved first-line treatment.
Case description: A 16-year-old male presented with recurrent fever, night sweats and several other non-specific symptoms. After extensive evaluations, an excisional lymph node biopsy confirmed the iMCD-NOS diagnosis. The patient received high-dose steroid therapy followed by siltuximab for four years. This treatment was well tolerated with only mild neutropenia not leading to dose adjustment. On siltuximab, the patient developed two mild COVID-19 episodes. His response to siltuximab remained effective throughout four years.
Discussion: The absence of biomarker or causal agent identification poses a diagnostic challenge requiring lymph node histopathology for a definitive diagnosis of iMCD. Anti-IL 6 (siltuximab) is the recommended frontline therapy, suppressing inflammation and halting disease progression. Intravenous administration every 3 to 6 weeks can impact patient quality of life, prompting further research for alternative treatments. High-dose steroids, rituximab, cyclosporine, tacrolimus, lenalidomide or combined chemotherapy such as rituximab-bortezomib-dexamethasone are among the considered options according to disease severity.
Conclusion: Overall, long-term siltuximab effectively controlled iMCD symptoms and was well tolerated by this young adult, who endured two mild COVID-19 episodes.

VIEW THE ENTIRE ARTICLE

References

  • Carbone A, Borok M, Damania B, Gloghini A, Polizzotto MN, Jayanthan RK, et al. Castleman disease. Nat Rev Dis Primers 2021;7:84.
  • Van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 2018;132:2115–2124.
  • Pierson SK, Lim MS, Srkalovic G, Brandstadter JD, Bustamante MS, Shyamsundar S, et al. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes. Blood Adv 2023;7:6652–6664.
  • Pai R-AL, Japp AS, Gonzalez M, Rasheed RF, Okumura M, Arenas D, et al. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. JCI Insight 2020;5:e135031.
  • Van Rhee F, Rosenthal A, Kanhai K, Martin R, Nishimura K, Hoering A, et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv 2022;6:4773–4781.
  • Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBDO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022;36:1720–1748.
  • Rehman MEU, Chattaraj A, Neupane K, Rafae A, Saeed S, Basit J, et al. Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: a systematic review. Eur J Haematol. 2022;109:309–320.
  • Yin X, Liu Y, Zhong C, Lv Y, Xu D, Zhu L, et al. Rituximab–bortezomib–dexamethasone induce high response rates in IMCD in clinical practice. Br J Haematol 2023:doi: 10.1111/bjh.19000
  • The REMAP-CAP investigators; Gordon AC, Mouncey PR, Al-Beidh F, Rowan KF, Nichol AD, Araby YM, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med 2021;384:1491–1502.
  • Lust H, Gong S, Remiker A, Rossoff J. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: a pediatric case series. Pediatr Blood Cancer 2021;68:e29261.
  • Lang E, Sande B, Brodkin S, Van Rhee F. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report. Ther Adv Hematol 2022;13:204062072210825.
  • Oshima K, Kanamori H, Takei K, Baba H, Tokuda K. Severe coronavirus disease 2019 in a patient with TAFRO syndrome: a case report. Clin Infect Pract 2022;16:100158.
  • Views: 452
    HTML downloads: 39
    PDF downloads: 303


    Published: 2023-11-17
    Issue: 2023: Vol 10 No 12 (view)


    How to cite:
    1.
    Bedier H, Isnard S, Maedler-Kron C, Routy J-P. Long-term tolerance and efficacy of siltuximab (anti-IL-6) in a young adult with idiopathic multicentric Castleman disease during COVID-19. EJCRIM 2023;10 doi:10.12890/2023_004098.

    Most read articles by the same author(s)